Qingqu Guo1, Muxing Kang, Bo Zhang, Ying Chen, Xin Dong, Yulian Wu. 1. Department of Surgery, The Second Affiliated Hospital, College of Medicine, Cancer Institute, Zhejiang University, 88# Jiefang Road, Hangzhou 310009, People's Republic of China.
Abstract
BACKGROUND: The relationship between diabetes and pancreatic cancer has been established by more than several decades of research. However, serum levels of CEA and CA 19-9 in diabetic pancreatic cancer has not been shown. METHODS: Preoperative serum levels of CEA and CA 19-9 and clinicopathological characteristics were retrospectively analyzed in 79 with or 229 without diabetes in pancreatic ductal adenocarcinoma (PDA) patients. RESULTS: Of the 308 PDA patients enrolled, 79 (25.6%) patients had diabetes. The percentage of new-onset diabetes (i.e. <24 months in duration) was 57% (45/79) in PDA patients coupled with diabetes. Among diabetic PDA patients, mean total bilirubin and fasting blood glucose significantly increased in comparison with control groups (8.54 ± 14.88 vs. 4.16 ± 6.12; 170.22 ± 106.96 vs. 95.84 ± 15.76; P < 0.05). No significant differences were observed in mean levels of serum CA 19-9 and CEA levels between two groups. However, when the value of CEA and CA 19-9 was analyzed as a dichotomous variable, elevated CEA (≥5 ng/ml) and CA 19-9 (≥500 U/ml) levels were strongly correlated with the presence of diabetes in PDA patients. CONCLUSION: Elevated CEA (≥5 ng/ml) and CA19-9 (≥500 U/ml) levels have an association with diabetic pancreatic cancer. New-onset diabetes combined with higher CA 19-9 and/or CEA might be regarded as a useful tool to screen early pancreatic cancer.
BACKGROUND: The relationship between diabetes and pancreatic cancer has been established by more than several decades of research. However, serum levels of CEA and CA 19-9 in diabetic pancreatic cancer has not been shown. METHODS: Preoperative serum levels of CEA and CA 19-9 and clinicopathological characteristics were retrospectively analyzed in 79 with or 229 without diabetes in pancreatic ductal adenocarcinoma (PDA) patients. RESULTS: Of the 308 PDA patients enrolled, 79 (25.6%) patients had diabetes. The percentage of new-onset diabetes (i.e. <24 months in duration) was 57% (45/79) in PDA patients coupled with diabetes. Among diabetic PDA patients, mean total bilirubin and fasting blood glucose significantly increased in comparison with control groups (8.54 ± 14.88 vs. 4.16 ± 6.12; 170.22 ± 106.96 vs. 95.84 ± 15.76; P < 0.05). No significant differences were observed in mean levels of serum CA 19-9 and CEA levels between two groups. However, when the value of CEA and CA 19-9 was analyzed as a dichotomous variable, elevated CEA (≥5 ng/ml) and CA 19-9 (≥500 U/ml) levels were strongly correlated with the presence of diabetes in PDA patients. CONCLUSION: Elevated CEA (≥5 ng/ml) and CA19-9 (≥500 U/ml) levels have an association with diabetic pancreatic cancer. New-onset diabetes combined with higher CA 19-9 and/or CEA might be regarded as a useful tool to screen early pancreatic cancer.
Authors: Suresh T Chari; Cynthia L Leibson; Kari G Rabe; Lawrence J Timmons; Jeanine Ransom; Mariza de Andrade; Gloria M Petersen Journal: Gastroenterology Date: 2007-10-26 Impact factor: 22.682
Authors: Fernando Rivera; Sara López-Tarruella; Ma Eugenia Vega-Villegas; Matilde Salcedo Journal: Cancer Treat Rev Date: 2009-01-07 Impact factor: 12.111
Authors: Clemens Hufnagl; Michael Leisch; Lukas Weiss; Thomas Melchardt; Martin Moik; Daniela Asslaber; Geisberger Roland; Philipp Steininger; Thomas Meissnitzer; Daniel Neureiter; Richard Greil; Alexander Egle Journal: Oncol Lett Date: 2019-12-09 Impact factor: 2.967
Authors: Neus Martinez-Bosch; Luis E Barranco; Carlos A Orozco; Mireia Moreno; Laura Visa; Mar Iglesias; Lucy Oldfield; John P Neoptolemos; William Greenhalf; Julie Earl; Alfredo Carrato; Eithne Costello; Pilar Navarro Journal: Oncotarget Date: 2018-08-31